시장보고서
상품코드
1149522

세계의 동물용 백신 시장 인사이트, 경쟁 구도, 시장 예측(2027년)

Veterinary Vaccines Market Insights, Competitive Landscape and, Market Forecast - 2027

발행일: | 리서치사: DelveInsight Business Research LLP | 페이지 정보: 영문 100 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 동물용 백신 시장 규모는 97억 8,000만 달러에서 2027년까지 164억 7,000만 달러에 이르고, 2022-2027년간 연평균 복합 성장률(CAGR) 9.13%의 성장이 전망되고 있습니다.

세계의 동물용 백신(Veterinary Vaccines) 시장에 대해 조사분석했으며, 시장 인사이트, 부문 분석, 지역 분석, 경쟁 구도 등의 정보를 전해드립니다.

목차

제1장 동물용 백신 시장 보고서 서론

제2장 동물용 백신 시장 개요

제3장 규제 분석

  • 미국
  • 유럽
  • 일본
  • 중국

제4장 동물용 백신 시장의 주요 요인 분석

  • 동물용 백신 시장 성장 촉진요인
  • 동물용 백신 시장 성장 억제요인과 과제
  • 동물용 백신 시장 기회

제5장 동물용 백신 시장 : Porter's Five Forces 분석

제6장 동물용 백신 시장에 대한 COVID-19의 영향 분석

제7장 동물용 백신 시장 레이아웃

  • 유형별
    • 불활성화 백신
    • 약독 생백신
    • 아단위 백신
    • 재조합 백신
    • 바이러스 벡터 백신
    • 기타
  • 적응증별
    • 바이러스
    • 세균
  • 동물 그룹별
    • 가금류
    • 가축
    • 반려동물
  • 최종사용자별
    • 동물병원
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 기타 지역(RoW)

제8장 동물용 백신 시장 : 기업과 제품 개요

  • Hester BiOSciences Limited
  • Boehringer Ingelheim International GmbH
  • Zoetis Services LLC
  • Elanco
  • Merck & Co., Inc
  • Indian Immunologicals Ltd.
  • Phibro Animal Health Corporation
  • Biogenesis Bago(R)
  • HIPRA
  • ARKO
  • Kyoto Biken Laboratories, Inc.
  • Vaxxinova(R) International BV
  • Dyntec s. r. o.
  • Brilliant Bio Pharma
  • BioTestLab
  • Virbac
  • KBNP
  • BIMEDA
  • VAKSINDO ANIMAL HEALTH PVT. LTD
  • Shchelkovo biocombinat

제9장 KOL의 견해

제10장 프로젝트 접근

제11장 DelveInsight에 대해

제12장 면책사항과 연락처

LSH 22.11.24

VETERINARY VACCINES MARKET BY TYPE (INACTIVATED VETERINARY VACCINES , LIVE-ATTENUATED VETERINARY VACCINES , SUBUNIT VETERINARY VACCINES, RECOMBINANT VETERINARY VACCINES, AND VIRAL VECTOR VETERINARY VACCINES), BY INDICATION (VIRAL, BACTERIAL, AND OTHERS), BY ANIMAL GROUP (POULTRY, LIVESTOCK, COMPANION ANIMALS, AND OTHERS), BY END-USER (VETERINARY CLINICS AND OTHERS), AND BY GEOGRAPHY IS EXPECTED TO ADVANCE AT A RESPECTABLE CAGR FORECAST TILL 2027 OWING TO INCREASING INCIDENCES OF ZOONOTIC DISEASES AND GROWING FOCUS ON REGULAR IMMUNIZATION SCHEDULE OF ANIMALS.

The global veterinary vaccines market was valued to be USD 9.78 billion, and will grow at a CAGR of 9.13% during the forecast period from 2022 to 2027 in order to reach USD 16.47 billion by 2027. The veterinary vaccines market is witnessing a positive market growth owing to the factors such as increasing incidences of zoonotic diseases, rising concern over antimicrobial resistance in animals, rising demand for safe and efficient food production, among others. Moreover, the growing focus on reducing animal morbidity and mortality rates due to preventable diseases in animals through regular immunization is another prominent factor leading to appreciable revenue growth in the veterinary vaccines market during the forecast period (2022-2027).

VETERINARY VACCINES MARKET DYNAMICS:

One of the key aspects driving the veterinary vaccines market is the rising incidences of zoonotic diseases such as Rabies, ZIKV virus, Ebola virus, and SARS-CoV among others.

Rabies, a highly contagious and fatal zoonotic disease affecting dogs, cats, foxes, humans, and other animals is one of the major factor responsible for the growth of veterinary vaccines market. As per American Veterinary Medical Association 2020 data, around 4,500 cases of rabies among animals were reported in 2020 in the US.

According to World Health Organization 2021, every year more than 29 million people worldwide receive a post-bite rabies vaccination. Also, as per the same source, globally, the total economic burden of dog-mediated rabies annually is estimated at USD 8.6 billion. The 99% cases of human rabies are from the bite of rabies infected dog. Thus necessitating the immunization of dogs against rabies to prevent serious consequences, positively impacting the veterinary vaccines market.

Nobivac® Rabies is inactivated vaccine for dogs, cats, cattle, sheep, goats, horses against Rabies.

Moreover, the increasing concern on antimicrobial resistance owing to over-use and misuse of antibiotics in veterinary medicine is likely to increase the demand for veterinary vaccines. The vaccines against antimicrobial-resistant pathogens not only prevent the animal from dangerous life threating diseases but also reduce the use of antibiotics, thereby lowering down the chances of development of antimicrobial resistance in animals. The risk of transmission of antimicrobial resistance to humans via animal food products is another major concern that can be tackled with the use of vaccines in animals against multiple antimicrobial resistance pathogens.

The continuous rise in government awareness programs on importance of animal vaccines is another factor playing essential part in increasing the demand for veterinary vaccines. For example, in 2019, government of India launched National Animal Disease Control Programme (NADCP) under which 100% of cattle, buffalo, sheep, goat and pig population will be vaccinated for Foot & Mouth Disease and 100% bovine female calves of 4-8 months of age for brucellosis with the aim of controlling both Foot & Mouth Disease and Brucellosis.

However, lack of awareness and access to veterinary vaccines and stringent government regulations for veterinary vaccines may prove to be challenging factors for veterinary vaccines market growth.

The veterinary vaccines market was slightly impacted during the period of COVID- 19 pandemic owing to the implementation of measures to curb the spread of the COVID-19 infection. The COVID- 19 pandemic led to lockdown implementation and border closures across the globe leading to halt in manufacturing and supply of veterinary vaccines. Also, the import and export of veterinary vaccines was majorly affected. However, with the resumption of activities across industries including the healthcare sector, there has been rising demand for the veterinary vaccines owing to resumption of suspended animal immunization schedules. The post COVID scenario is going to be uplifting for the veterinary vaccines market during the forecast period from 2022-2027.

VETERINARY VACCINES MARKET SEGMENT ANALYSIS:

Veterinary Vaccines Market by Type (Inactivated Veterinary Vaccines, Live-Attenuated Veterinary Vaccines, Subunit Veterinary Vaccines, Recombinant Veterinary Vaccines, and Viral Vector Veterinary Vaccines), Indication (Viral, Bacterial, and Others), Animal Group (Poultry, Livestock, Companion Animals, and Others), End-Users (Veterinary Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the type segment of the veterinary vaccines market, the viral vector category is estimated to grow at a CAGR of xx during the forecast period from 2022 to 2027 to reach USD xx million by 2027. This can be attributed to advantages associated with viral vectored veterinary vaccines.

The viral vectors such as adenovirus, herpesvirus and poxviruses are majorly employed in the production of veterinary vaccines.

The viral vectored animal vaccines have number of benefits over conventional vaccine types such as they are safer, stable, and are efficient even in the absence of an adjuvant. They do not usually lead to any kind of adverse reaction in animals and can be adjusted to meet the growing disease challenges.

In case of certain serious animal diseases, viral vectored veterinary vaccines are more effective and good option over other vaccine types available. For example, animals such sheep, goat, and others can be protected against Rift Valley fever virus (RVFV) with a single dose administration of recombinant adenovirus RVFV vaccine.

Also, the bypassing of maternal immunity has been evident for recombinant adenovirus vaccines such as against herpes virus which causes Aujeszky's disease in pigs.

Therefore, considering the growing demand for this product type, numerous new products are being launched in the market. For example, In May 2021, Boehringer Ingelheim launched poultry viral vector vaccine named VAXXITEK® HVT+IBD in India. The vaccine provide immunity to chickens, namely broiler, layer and breeder against three diseases including Marek's Disease (MD), Infectious Bursal Disease (IBD) and Newcastle disease (ND)

Therefore, owing to the advantages and applications associated with viral vectored veterinary vaccines, the product category is expected to witness a considerable growth eventually contributing to the overall growth of the global veterinary vaccines market during the forecast period.

NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL VETERINARY VACCINES MARKET:

Among all the regions, North America is estimated to grow at a CAGR of xx during the forecast period from 2022 to 2027 to reach USD xx million by 2027. This can be ascribed to the increasing prevalence of animal diseases such as rabies and others, high disposable income, sophisticated veterinary healthcare infrastructure, and presence of key players in the region among others.

One of the key supporting factors for the growth of the North America Veterinary Vaccines Market is the increasing prevalence of rabies among animals in the United States. As per the figures mentioned by the Texas Department of State Health Services 2021, there were around 455 cases of rabies reported in Texas in 2021. According to New Jersey Department of Health 2021 data, around 257 cases of rabies were reported positive in 2020 in New Jersey. As per the California Department of Public Health 2021 statistics, around 220 cases of animal rabies were reported in 2020 in California.

Another aspect stimulating the growth of the United States veterinary vaccines market is the large number of pet owners in the country as companion animals are required to be routinely vaccinated in order to avoid serious consequences from diseases. According to APPA National Pet Owners Survey 2021-2022, around 70% of the US household that is around 90.5 million homes own a pet in the US. As per the same source around 69.0 million households are dog owners and approx 45.3 million households are cat owners. Dogs are required to be annually administered with vaccines against number of deadly diseases such as rabies, Coronavirus, Parvovirus, and others.

Therefore, the large number of pet owners and prevalence of animal diseases in the region is expected to contribute in the growth of the veterinary vaccines market in the United States. Thus, propelling the growth of North America region market.

VETERINARY VACCINES MARKET KEY PLAYERS:

Some of the key market players operating in the veterinary vaccines market includes Hester Biosciences Limited, Boehringer Ingelheim International GmbH, Zoetis Services LLC, Elanco, Merck & Co., Inc., Indian Immunologicals Ltd., Phibro Animal Health Corporation, Biogenesis Bago®, HIPRA, ARKO, Kyoto Biken Laboratories, Inc., Vaxxinova® International BV, Dyntec s. r. o., Brilliant Bio Pharma, BioTestLab, Virbac, KBNP, BIMEDA, Shchelkovo biocombinat, VAKSINDO ANIMAL HEALTH PVT. LTD, and others.

RECENT DEVELOPMENTAL ACTIVITIES IN VETERINARY VACCINES MARKET:

  • In September 2022, Boehringer Ingelheim launched Fencovis® which is the first vaccine against calf disease.
  • In June 2022, India's first homegrown COVID-19 vaccine Anocovax for animals, produced by the ICAR-National Research Centre on Equines (NRCE) was launched in India.
  • In April 2022, Ceva Animal Health launched Ibird vaccine against Infectious Bronchitis in India.

KEY TAKEAWAYS FROM THE VETERINARY VACCINES MARKET REPORT STUDY

  • Market size analysis for current veterinary vaccines market size (2020), and market forecast for 5 years (2021-2027)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the veterinary vaccines market.
  • Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
  • Key companies dominating the global veterinary vaccines market.
  • Various opportunities available for the other competitor in the veterinary vaccines market space.
  • What are the top performing segments in 2020? How these segments will perform in 2027.
  • Which is the top-performing regions and countries in the current veterinary vaccines market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for veterinary vaccines market growth in the coming future?

TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS VETERINARY VACCINES MARKET REPORT STUDY

  • Veterinary Vaccines products providers
  • Research organizations and consulting companies
  • Veterinary Vaccines -related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in veterinary vaccines
  • Various end users who want to know more about the veterinary vaccines market and latest technological developments in the veterinary vaccines market.

FREQUENTLY ASKED QUESTIONS FOR VETERINARY VACCINES MARKET:

1. What is Veterinary Vaccines?

Veterinary vaccines are preparations that contain a weakened or killed form of pathogen or their part or any other form such that it is no longer virulent (ability to cause disease) in order to imbibe active immunity in a animal in which it is administered by triggering the adaptive immune response.

2. What is the global market for Veterinary Vaccines?

The global veterinary vaccines market was valued to be USD 9.78 billion, and will grow at a CAGR of 9.13% during the forecast period from 2022 to 2027 in order to reach USD 16.47 billion by 2027.

3. What are the drivers for Global Veterinary Vaccines Market?

The veterinary vaccines market is witnessing a positive market growth owing to the factors such as rising prevalence of multiple animal diseases such as rabies, food & mouth disease, coronavirus, and others that are contributing in the growing demand for veterinary vaccines. Moreover, the growing focus on reducing animal morbidity and mortality rates due to preventable diseases in animals is another prominent factor responsible for the growth of the veterinary vaccines market. Additionally, the rising concern over antimicrobial resistance in animals is creating an exigency for the veterinary vaccines.

4. Who are the key players operating in the global veterinary vaccines market?

Some of the key market players operating in the Veterinary Vaccines Market includes Hester Biosciences Limited, Boehringer Ingelheim International GmbH, Zoetis Services LLC, Elanco, Merck & Co., Inc., Indian Immunologicals Ltd., Phibro Animal Health Corporation, Biogenesis Bago®, HIPRA, ARKO, Kyoto Biken Laboratories, Inc., Vaxxinova® International BV, Dyntec s. r. o., Brilliant Bio Pharma , BioTestLab, Virbac, KBNP, BIMEDA, Shchelkovo biocombinat, VAKSINDO ANIMAL HEALTH PVT. LTD, and others.

5. Which region has the highest share in Veterinary Vaccines Market?

Among all the regions, North America is estimated to amass the significant revenue share in the global veterinary vaccines market. This can be ascribed to the increasing prevalence of animal diseases, and large number of pet owners in the region, particularly in the United States. Furthermore, high disposable income, sophisticated veterinary healthcare infrastructure, and presence of key market players in the region is another factor that acts as a supportive factor for the North America veterinary vaccines market growth.

Table of Contents

1. Veterinary Vaccines Market Report Introduction

2. Veterinary Vaccines Market Executive Summary

  • 2.1 Scope of the Study
  • 2.2 Market at Glance
  • 2.3 Competitive Assessment
  • 2.4 Financial Benchmarking

3. Regulatory Analysis

  • 3.1 The United States
  • 3.2 Europe
  • 3.3 Japan
  • 3.4 China

4. Veterinary Vaccines Market Key Factors Analysis

  • 4.1 Veterinary Vaccines Market Drivers
    • 4.1.1 Increasing incidences of zoonotic diseases
    • 4.1.2 Rise in number of regular immunization schedule of animals
    • 4.1.3 Increasing concern over antimicrobial resistance in animals
    • 4.1.4 Rising demand for safe and efficient food production
  • 4.2 Veterinary Vaccines Market Restraints and Challenges
    • 4.2.1 Lack of awareness and access to veterinary vaccines
    • 4.2.2 Stringent government regulations for veterinary vaccines
  • 4.3 Veterinary Vaccines Market Opportunities
    • 4.3.1 Increasing government and non-government programs to maintain animal health
    • 4.3.2 Development of affordable and safer veterinary vaccines with minimal side-effects

5. Veterinary Vaccines Market Porter's Five Forces Analysis

  • 5.1 Bargaining Power of Suppliers
  • 5.2 Bargaining Power of Consumers
  • 5.3 Threat of New Entrants
  • 5.4 Threat of Substitutes
  • 5.5 Competitive Rivalry

6. COVID-19 Impact Analysis on Veterinary Vaccines Market

7. Veterinary Vaccines Market Layout

  • 7.1 By Type
    • 7.1.1 Inactivated Veterinary Vaccines
    • 7.1.2 Live-Attenuated Veterinary Vaccines
    • 7.1.3 Subunit Veterinary Vaccines
    • 7.1.4 Recombinant Veterinary Vaccines
    • 7.1.5 Viral Vector Veterinary Vaccines
    • 7.1.6 Others
  • 7.2 By Indication
    • 7.2.1 Viral
    • 7.2.2 Bacterial
    • 7.2.3 Others
  • 7.3 By Animal Group
    • 7.3.1 Poultry
    • 7.3.2 Livestock
    • 7.3.3 Companion animals
    • 7.3.4 Others
  • 7.4 By End-User
    • 7.4.1 Veterinary Clinics
    • 7.4.2 Others
  • 7.5 By Geography
  • 7.5.1 North America
      • 7.5.1.1 United States Veterinary Vaccines Market in USD million (2019-2027)
      • 7.5.1.2 Canada Veterinary Vaccines Market in USD million (2019-2027)
      • 7.5.1.3 Mexico Veterinary Vaccines Market in USD million (2019-2027)
    • 7.5.2 Europe
      • 7.5.2.1 France Veterinary Vaccines Market in USD million (2019-2027)
      • 7.5.2.2 Germany Veterinary Vaccines Market in USD million (2019-2027)
      • 7.5.2.3 United Kingdom Veterinary Vaccines Market in USD million (2019-2027)
      • 7.5.2.4 Italy Veterinary Vaccines Market in USD million (2019-2027)
      • 7.5.2.5 Spain Veterinary Vaccines Market in USD million (2019-2027)
      • 7.5.2.6 Russia Veterinary Vaccines Market in USD million (2019-2027)
      • 7.5.2.7 Rest of Europe Veterinary Vaccines Market in USD million (2019-2027)
    • 7.5.3 Asia-Pacific
      • 7.5.3.1 China Veterinary Vaccines Market in USD million (2019-2027)
      • 7.5.3.2 Japan Veterinary Vaccines Market in USD million (2019-2027)
      • 7.5.3.3 India Veterinary Vaccines Market in USD million (2019-2027)
      • 7.5.3.4 Australia Veterinary Vaccines Market in USD million (2019-2027)
      • 7.5.3.5 South Korea Veterinary Vaccines Market in USD million (2019-2027)
      • 7.5.3.6 Rest of Asia Pacific Veterinary Vaccines Market in USD million (2019-2027)
    • 7.5.4 Rest of the World (RoW)
      • 7.5.4.1. Middle East Veterinary Vaccines Market in USD million (2019-2027)
      • 7.5.4.2 Africa Veterinary Vaccines Market in USD million (2019-2027)
      • 7.5.4.3 South America Veterinary Vaccines Market in USD million (2019-2027)

8. Veterinary Vaccines Market Company and Product Profiles

  • 8.1 Hester Biosciences Limited
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4 Product Listing
    • 8.1.5. Entropy
  • 8.2 Boehringer Ingelheim International GmbH
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4 Product Listing
    • 8.2.5. Entropy
  • 8.3 Zoetis Services LLC
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4 Product Listing
    • 8.3.5. Entropy
  • 8.4 Elanco
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4 Product Listing
    • 8.4.5. Entropy
  • 8.5 Merck & Co., Inc
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4 Product Listing
    • 8.5.5. Entropy
  • 8.6 Indian Immunologicals Ltd.
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4 Product Listing
    • 8.6.5. Entropy
  • 8.7 Phibro Animal Health Corporation
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4 Product Listing
    • 8.7.5. Entropy
  • 8.8 Biogenesis Bago®
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4 Product Listing
    • 8.8.5. Entropy
  • 8.9 HIPRA
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4 Product Listing
    • 8.9.5. Entropy
  • 8.10 ARKO
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4 Product Listing
    • 8.10.5. Entropy
  • 8.11 Kyoto Biken Laboratories, Inc.
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4 Product Listing
    • 8.11.5. Entropy
  • 8.12 Vaxxinova® International BV
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4 Product Listing
    • 8.12.5. Entropy
  • 8.13 Dyntec s. r. o.
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4 Product Listing
    • 8.13.5. Entropy
  • 8.14 Brilliant Bio Pharma
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4 Product Listing
    • 8.14.5. Entropy
  • 8.15 BioTestLab
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4 Product Listing
    • 8.15.5. Entropy
  • 8.16 Virbac
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4 Product Listing
    • 8.16.5. Entropy
  • 8.17 KBNP
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4 Product Listing
    • 8.17.5. Entropy
  • 8.18 BIMEDA
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4 Product Listing
    • 8.18.5. Entropy
  • 8.19 VAKSINDO ANIMAL HEALTH PVT. LTD
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4 Product Listing
    • 8.19.5. Entropy
  • 8.20 Shchelkovo biocombinat
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4 Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제